Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2022 pubmed 3 citations

Differential effects of PEGylated Cd-free CuInS<sub>2</sub>/ZnS quantum dot (QDs) on substance P and LL-37 induced human mast cell activation.

Xia. Beibei B; Lin. Guimiao G; Zheng. Siman S; Zhang. Heng H; Yu. Yangyang Y

Key Findings

  • CuInS2/ZnS‑PEG quantum dots enter human mast cells without harming them
  • The dots block calcium‑driven degranulation caused by LL‑37 and Substance P
  • Low dot doses boost TNF‑α release with LL‑37, while higher doses suppress IL‑8 release

Practical Outcomes

  • For everyday health‑optimizing protocols, there’s no actionable takeaway—quantum dots aren’t a typical supplement. However, the data suggest that exposure to certain nanomaterials could alter immune signaling, so caution is advised if you encounter such particles in experimental or medical contexts.

Summary

The study looked at tiny, non‑toxic quantum dots (tiny particles used in imaging) and how they affect immune cells when the cells are triggered by the peptide LL‑37. The dots got inside the cells without killing them, but they changed how the cells reacted to LL‑37, sometimes boosting one inflammatory signal (TNF‑α) and lowering another (IL‑8). For most biohackers, this isn’t directly useful because quantum dots aren’t a common supplement or therapy, but it does show that nanomaterials can tweak immune responses.

Abstract

CuInS<sub>2</sub>/ZnS-PEG quantum dots (QDs) are among the most widely used near infrared non-cadmium QDs and are favored because of their non-cadmium content and strong tissue penetration. However, with their increasing use, there is great concern about whether exposure to QDs is potentially risky to the environment and humans. Furthermore, toxicological data related to CuInS<sub>2</sub>/ZnS-PEG QDs are scarce. In the study, we found that CuInS<sub>2</sub>/ZnS-PEG QDs (0-100&#xa0;&#x3bc;g/mL) could internalize into human LAD2 mast cells without affecting their survival rate, nor did it cause degranulation or release of IL-8 and TNF-&#x3b1;. However, CuInS<sub>2</sub>/ZnS-PEG QDs significantly inhibited Substance P (SP) and LL-37-induced degranulation and chemotaxis of LAD2 cells by inhibiting calcium mobilization. Lower concentrations of CuInS<sub>2</sub>/ZnS-PEG QDs promoted the release of TNF-&#x3b1; and IL-8 stimulated by SP, but higher concentrations of CuInS<sub>2</sub>/ZnS-PEG QDs significantly inhibited the release of TNF-&#x3b1; and IL-8. On the other hand, CuInS<sub>2</sub>/ZnS-PEG QDs promoted LL-37-mediated TNF-&#x3b1; release from LAD2 cells in a dose-dependent manner from 6.25 to 100&#xa0;&#x3bc;g/mL, while release of IL-8 triggered by LL-37 was dose-dependently inhibited within a dose concentration of 12.5-100&#xa0;&#x3bc;g/mL. Collectively, our data demonstrated that CuInS<sub>2</sub>/ZnS-PEG QDs differentially mediated human mast cell activation induced by SP and LL-37.

Study Information

Provider

pubmed

Year

2022

Date

2022-09-26T00:00:00.000Z

DOI

10.1016/j.ecoenv.2022.114108

Citations

3

References

51